| Identification | Back Directory | [Name]
Zanubrutinib | [CAS]
1691249-45-2 | [Synonyms]
anubrutinib
Zanubrutinib
The BTK inhibitor
BGB-3111(Zanubrutinib)
Zanubrutinib (BGB-3111)
BGB-3111;ZANUBRUTINIB;BGB 3111;BGB3111
(S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-, (7S)- | [Molecular Formula]
C27H29N5O3 | [MDL Number]
MFCD31567461 | [MOL File]
1691249-45-2.mol | [Molecular Weight]
471.55 |
| Chemical Properties | Back Directory | [Boiling point ]
713.4±60.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:99.67(Max Conc. mg/mL);211.36(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);21.21(Max Conc. mM)
DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.34(Max Conc. mM)
Ethanol:33.33(Max Conc. mg/mL);70.68(Max Conc. mM) | [form ]
A solid | [pka]
15.35±0.40(Predicted) |
| Hazard Information | Back Directory | [Uses]
Zanubrutinib is classified as a Bruton''s tyrosine kinase inhibitor. Zanubrutinib is a medication for the treatment of adults with mantle cell lymphoma. |
|
|